<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518554</url>
  </required_header>
  <id_info>
    <org_study_id>JAB-3068-01</org_study_id>
    <nct_id>NCT03518554</nct_id>
  </id_info>
  <brief_title>A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobio Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jacobio Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety,
      tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in
      adult patients with advanced solid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>up to 28-day per cycle</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-3068.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Area under the plasma concentration time curve of JAB-3068</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Highest observed plasma concentration of JAB-3068</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Time of highest observed plasma concentration of JAB-3068</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Half life of JAB-3068</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>ORR is defined as the proportion of participants with complete response or partial response (CR+PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pERK</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>On treatment versus baseline comparison of pharmacodynamic marker pERK (Phosphorylated form of Extracellular signal-regulated kinase) on newly obtained tumor biopsy samples by IHC.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Other Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>JAB-3068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral administration of JAB-3068</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-3068</intervention_name>
    <description>JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.</description>
    <arm_group_label>JAB-3068</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to any study-related procedure being
             performed;

          2. Age 18 years or older;

          3. Patients with histologically or cytologically confirmed, advanced solid tumors which
             have progressed despite standard therapy or for whom no standard therapy exists;

          4. Patients with life expectancy ≥3 months;

          5. Patients must have at least one measurable lesion as defined by RECIST v1.1;

          6. Eastern Cooperative Oncology Group performance score 0 or 1;

          7. Patients who have sufficient baseline organ function.

        Exclusion Criteria:

          1. Patients with life-threatening autoimmune disease or with autoimmune disorder and who
             are on long-term steroid treatment;

          2. History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO;

          3. Known malignant central nervous system (CNS) disease other than neurologically stable,
             treated brain metastases;

          4. Active infection including hepatitis B, hepatitis C and human immunodeficiency virus
             (HIV)

          5. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that, in the opinion of the Investigator and Sponsor, could affect the
             patient's participation in the study

          6. Patients who have impaired cardiac function or clinically significant cardiac
             diseases;

          7. Use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter)
             prior to the first dose of JAB-3068;

          8. Use of an investigational drug during the past 30 days or 5 half-lives (whichever is
             shorter) prior to the first dose of JAB-3068;

          9. No other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy
             radiotherapy (except for palliative local radiotherapy), biological therapy or other
             novel agent is to be permitted while the patient is receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Cai, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jacobio Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doug Cai, MD,PhD</last_name>
    <phone>(617)6695138</phone>
    <email>doug.cai@jacobiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Hanchey</last_name>
      <phone>941-377-9993</phone>
      <email>KHanchey@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Judy Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Karan</last_name>
    </contact>
    <contact_backup>
      <last_name>Kayla Karan</last_name>
      <phone>(615)3296815</phone>
      <email>Kayla.Karan@SarahCannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Todd M Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

